76 filings
Page 2 of 4
8-K
rjuwqf 7no
9 Jan 23
Results of Operations and Financial Condition
8:00am
8-K
lk3qllqji7ei9y5h nen
10 Nov 22
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
8:15am
EFFECT
v7xuxzodgefv 52ythc
10 Nov 22
Notice of effectiveness
12:00am
UPLOAD
nurx11n9pg7kk7u fj6o
8 Nov 22
Letter from SEC
12:00am
CORRESP
6ovg9n rd7fau2jzjxu
8 Nov 22
Correspondence with SEC
12:00am
8-K
ivy60jhwpq1yb
28 Oct 22
Submission of Matters to a Vote of Security Holders
4:05pm
DEFR14A
lw6jeys tw39
25 Oct 22
Revised proxy
5:27pm
8-K
blfjb
13 Oct 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
D
lo316 8va8439l
7 Oct 22
$16.19 mm in equity / options / securities to be acquired, sold $6.65 mm, 5 investors
5:32pm
8-K
px3rk 35rpfa
29 Sep 22
Anebulo Pharmaceuticals Announces $6.6 million Private Placement Financing
4:05pm
8-K
deq5ag
26 Sep 22
Regulation FD Disclosure
8:00am
8-K
9lxr2utldlc
9 Sep 22
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022
8:00am
8-K
0e73g
5 Jul 22
Regulation FD Disclosure
8:17am
8-K
fb9ewo629dlvnenla3ua
24 May 22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
4:05pm
8-K
nw3e9t
11 May 22
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
9:00am